中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 2
Feb.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(2): 319-325

Correlation between liver fibrosis degree and carotid plaque in patients with lean metabolic dysfunction-associated fatty liver disease

DOI: 10.12449/JCH260212
  • 1.

    Department of Gastroenterology，Subei People’s Hospital Affiliated to Yangzhou University，Yangzhou，Jiangsu 225001，China

  • 2.

    Department of Cardiology，Subei People’s Hospital Affiliated to Yangzhou University，Yangzhou，Jiangsu 225001，China

  • 3.

    Department of Hepatobiliary，Subei People’s Hospital Affiliated to Yangzhou University，Yangzhou，Jiangsu 225001，China

  • 4.

    Department of Gastrointestinal Surgery，Subei People’s Hospital Affiliated to Yangzhou University，Yangzhou，Jiangsu 225001，China

Research funding:

Jiangsu Provincial Basic Research Program （Natural Science Foundation） Youth Fund Project (BK20240498);

National Natural Science Foundation of China Youth Project (82400623)

More Information
  • Corresponding author: LIU Jun， sbyy_liujun@163.com （ORCID： 0000-0001-8738-6548）
  • Received Date: 2025-09-21
  • Accepted Date: 2025-10-27
  • Published Date: 2026-02-25
    Abstract
  •   Objective  To investigate the association between noninvasive liver fibrosis markers and carotid plaque （CP） in patients with lean metabolic dysfunction-associated fatty liver disease （MAFLD）， and to provide a basis for screening high-risk populations.  Methods  A total of 957 patients with lean MAFLD who underwent physical examination in Subei People’s Hospital from January 2021 to June 2023 was enrolled as the observation cohort， with the presence or absence of CP as the outcome， and fibrosis-4 （FIB-4） index and nonalcoholic fatty liver disease fibrosis score （NFS） were used to assess liver fibrosis degree. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. The multivariate logistic regression analysis， the restricted cubic spline analysis， the receiver operating characteristic curve， and the mediation effect analysis were used to investigate the association between liver fibrosis degree and CP.  Results  The prevalence rate of CP was 36.6% in the lean MAFLD population. Compared with the non-CP group（n=607）， the CP group （n=350） had a significantly higher proportion of male patients， a significantly higher proportion of patients with smoking/diabetes/hypertension， and significantly higher levels of age， creatinine， blood urea nitrogen， triglycerides， fasting blood glucose， aspartate aminotransferase， aspartate aminotransferase/alanine aminotransferase ratio， NFS， and FIB-4 index， as well as significantly lower levels of platelet count and albumin （all P<0.05）. The multivariate logistic regression analysis showed that after adjustment for confounding factors， FIB-4 index （odds ratio［OR］=2.979， 95% confidence interval［CI］：2.141 — 4.219， P<0.001） and NFS （OR=1.747， 95%CI： 1.499 — 2.046， P<0.001） were positively correlated with CP. Both FIB-4 index and NFS had a good value in predicting CP. Hypertension had a significant indirect effect on the prevalence rate of CP through its impact on liver fibrosis markers， and its mediating effect accounted for 39.5% — 40.8% of the total effect （P<0.001）.  Conclusion  In patients with lean MAFLD， NFS and FIB-4 index are significantly positively correlated with the prevalence rate of CP， and they can be used as potential epidemiological predictive indicators. Liver fibrosis markers may play a mediating role in the association between hypertension and CP. Interventions targeting hypertension and liver fibrosis markers may help to prevent and delay the progression of CP.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79( 6): 1542- 1556. DOI: 10.1016/j.jhep.2023.06.003.
    [2]
    WEI YX, ZHOU XD, ZHENG MH. Heart and liver co-management: integrated management of metabolic dysfunctionassociated steatotic liver disease with cardiovascular disease[J/CD]. Chin J Liver Dis(Electronic Version), 2025, 17( 3): 1- 9. DOI: 10.3969/j.issn.1674-7380.2025.03.001.

    韦艺轩, 周晓东, 郑明华. 心肝共治: 代谢相关脂肪性肝病合并心血管疾病风险的协同管理[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 3): 1- 9. DOI: 10.3969/j.issn.1674-7380.2025.03.001.
    [3]
    ZHANG C, ZHU PH, HE LL. Research progress on the correlation between metabolic associated fatty liver disease and cardiovascular disease risk[J/CD]. Chin J Liver Dis(Electronic Version), 2025, 17( 1): 12- 18. DOI: 10.3969/j.issn.1674-7380.2025.01.003.

    张成, 朱平辉, 何玲玲. 代谢相关脂肪性肝病与心血管疾病风险相关性研究现状[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 1): 12- 18. DOI: 10.3969/j.issn.1674-7380.2025.01.003.
    [4]
    LEE HH, LEE HA, KIM EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease[J]. Gut, 2024, 73( 3): 533- 540. DOI: 10.1136/gutjnl-2023-331003.
    [5]
    CHAN KE, KOH TJL, TANG ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: A meta-analysis and systematic review of 10 739 607 individuals[J]. J Clin Endocrinol Metab, 2022, 107( 9): 2691- 2700. DOI: 10.1210/clinem/dgac321.
    [6]
    SOUZA M, DIAZ I, AL-SHARIF L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: An updated systematic review and meta-analysis of about 1 million individuals[J]. Hepatol Int, 2024, 18( 5): 1396- 1415. DOI: 10.1007/s12072-024-10716-z.
    [7]
    SABA L, SAAM T, JÄGER HR, et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications[J]. Lancet Neurol, 2019, 18( 6): 559- 572. DOI: 10.1016/S1474-4422(19)30035-3.
    [8]
    BADMUS OO, HINDS TD, STEC DE. Mechanisms linking metabolic-associated fatty liver disease(MAFLD) to cardiovascular disease[J]. Curr Hypertens Rep, 2023, 25( 8): 151- 162. DOI: 10.1007/s11906-023-01242-8.
    [9]
    SIMON TG, ROELSTRAETE B, HAGSTRÖM H, et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: Results from a nationwide histology cohort[J]. Gut, 2022, 71( 9): 1867- 1875. DOI: 10.1136/gutjnl-2021-325724.
    [10]
    National Clinical Practice Guideline on Obesity Management Editorial Committee. National clinical practice guideline on obesity management(2024 edition)[J]. Chin Circ J, 2025, 40( 1): 6- 30. DOI: 10.3969/j.issn.1000-3614.2025.01.002.

    国家卫生健康委员会肥胖症诊疗指南编写委员会. 肥胖症诊疗指南(2024年版)[J]. 中国循环杂志, 2025, 40( 1): 6- 30. DOI: 10.3969/j.issn.1000-3614.2025.01.002.
    [11]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of alcohol-related liver disease[J]. J Hepatol, 2018, 69( 1): 154- 181. DOI: 10.1016/j.jhep.2018.03.018.
    [12]
    ESLAM M, FAN JG, YU ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int, 2025, 19( 2): 261- 301. DOI: 10.1007/s12072-024-10774-3.
    [13]
    MATHIESEN EB, JOHNSEN SH. Ultrasonographic measurements of subclinical carotid atherosclerosis in prediction of ischemic stroke[J]. Acta Neurol Scand, 2009, 120: 68- 72. DOI: 10.1111/j.1600-0404.2009.01210.x.
    [14]
    LEE J, VALI Y, BOURSIER J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review[J]. Liver Int, 2021, 41( 2): 261- 270. DOI: 10.1111/liv.14669.
    [15]
    TIAN YB, NIU H, XU F, et al. ALBI score combined with FIB-4 index to predict post-hepatectomy liver failure in patients with hepatocellular carcinoma[J]. Sci Rep, 2024, 14( 1): 8034. DOI: 10.1038/s41598-024-58205-5.
    [16]
    LIEBE R, ESPOSITO I, BOCK HH, et al. Diagnosis and management of secondary causes of steatohepatitis[J]. J Hepatol, 2021, 74( 6): 1455- 1471. DOI: 10.1016/j.jhep.2021.01.045.
    [17]
    YOUNG S, TARIQ R, PROVENZA J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: Systematic review and meta-analysis[J]. Hepatol Commun, 2020, 4( 7): 953- 972. DOI: 10.1002/hep4.1519.
    [18]
    ZHU YD, ZHANG ZJ, ZHANG GL, et al. Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis[J]. J Clin Hepatol, 2024, 40( 8): 1591- 1597. DOI: 10.12449/JCH240814.

    朱英嵽, 张志娇, 张桂林, 等. 代谢相关脂肪性肝病与颈动脉粥样硬化斑块及狭窄的关联分析[J]. 临床肝胆病杂志, 2024, 40( 8): 1591- 1597. DOI: 10.12449/JCH240814.
    [19]
    ZOU B, YEO YH, NGUYEN VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016[J]. J Intern Med, 2020, 288( 1): 139- 151. DOI: 10.1111/joim.13069.
    [20]
    KIM Y, HAN E, LEE JS, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease[J]. Gut Liver, 2022, 16( 2): 290- 299. DOI: 10.5009/gnl210084.
    [21]
    XUE JF, ZHAO L, SHAO L, et al. Higher risk of carotid plaque among lean individuals with non-alcoholic fatty liver disease: A retrospective study[J]. PLoS One, 2025, 20( 2): e0316997. DOI: 10.1371/journal.pone.0316997.
    [22]
    WANG YQ, YUAN T, DENG SW, et al. Metabolic health phenotype better predicts subclinical atherosclerosis than body mass index-based obesity phenotype in the non-alcoholic fatty liver disease population[J]. Front Nutr, 2023, 10: 1104859. DOI: 10.3389/fnut.2023.1104859.
    [23]
    MEHAL W. Mechanisms of liver fibrosis in metabolic syndrome[J]. eGastroenterology, 2023, 1( 1): e100015. DOI: 10.1136/egastro-2023-100015.
    [24]
    ZHANG J, LI L, LIN L, et al. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD[J]. BMC Public Health, 2025, 25( 1): 2747. DOI: 10.1186/s12889-025-23883-x.
    [25]
    CHEKOL ABEBE E, TILAHUN MUCHE Z, BEHAILE T/MARIAM A, et al. The structure, biosynthesis, and biological roles of fetuin-A: A review[J]. Front Cell Dev Biol, 2022, 10: 945287. DOI: 10.3389/fcell.2022.945287.
    [26]
    MI P. CD36, a scavenger receptor implicated in atherosclerosis[J]. Exp Mol Med, 2014, 46( 6): e99. DOI: 10.1038/emm.2014.38.
    [27]
    MCMURRY HS, JOU J, SHATZEL J. The hemostatic and thrombotic complications of liver disease[J]. Eur J Haematol, 2021, 107( 4): 383- 392. DOI: 10.1111/ejh.13688.
    [28]
    GAO ZF, DENG H, QIN BW, et al. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease[J]. Front Med, 2025, 12: 1539283. DOI: 10.3389/fmed.2025.1539283.
    [29]
    LI W, LIU ZR, ZHAO JQ, et al. Association of systolic blood pressure time in target range with carotid atherosclerotic plaque and carotid intima-media thickness in hypertensive patients[J]. Sci Rep, 2025, 15( 1): 17347. DOI: 10.1038/s41598-025-01217-6.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (31) PDF downloads(11) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return